Integrins and adhesion molecules as targets to treat inflammatory bowel disease

Ivana Bravatà; Mariangela Allocca; Gionata Fiorino; Silvio Danese

doi:10.1016/j.coph.2015.11.007

Integrins and adhesion molecules as targets to treat inflammatory bowel disease

Curr Opin Pharmacol. 2015 Dec:25:67-71. doi: 10.1016/j.coph.2015.11.007.

Authors

Ivana Bravatà¹, Mariangela Allocca¹, Gionata Fiorino¹, Silvio Danese²

Affiliations

¹ IBD Center, Gastroenterology, IRCCS Humanitas, Rozzano, Milan, Italy.
² IBD Center, Gastroenterology, IRCCS Humanitas, Rozzano, Milan, Italy; Humanitas University, Department of Biomedical Sciences, Rozzano, Milan, Italy. Electronic address: sdanese@hotmail.com.

PMID: 26687159
DOI: 10.1016/j.coph.2015.11.007

Abstract

Inflammatory bowel diseases (IBD) present a typically relapsing-remitting behavior and are characterized by a disabling and progressive course. Anti-tumor necrosis factor (TNF)-α agents have drastically changed the therapeutic management of IBD. However, a significant proportion of patients does not have a primary response, some patients lose response overtime and/or experience side effects. Recently, anti-adhesion molecules were investigated and showed efficacy with a good safety profile. Vedolizumab was recently approved for both Crohn's disease (CD) and ulcerative colitis (UC) and several other molecules are under evaluation in this field. Anti-adhesion molecules could represent a potential therapeutic option for future therapy in IBD. In this review we report the efficacy and safety of major anti-adhesion drugs in active IBD patients.

Publication types

Review

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use
Cell Adhesion Molecules / antagonists & inhibitors*
Humans
Inflammatory Bowel Diseases / drug therapy*
Inflammatory Bowel Diseases / metabolism*
Integrins / antagonists & inhibitors*
Models, Biological
Molecular Targeted Therapy / methods*

Substances

Antibodies, Monoclonal, Humanized
Cell Adhesion Molecules
Integrins